From Novartis, Bristol MS meds to new ADCs, here are 2020’s blockbuster drug launches
Novo’s next-gen GLP-1 Ozempic smashes blockbuster barrier amid ramp-up for Rybelsus rollout
Novo Nordisk Snags FDA Approval for Oral Type 2 Diabetes Drug
Clinical Catch-up for June 10-14
ADA: Novo Nordisk’s oral semaglutide posts another heart safety win
Lilly’s Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Novo Nordisk’s Ozempic Continues to Show Superiority in Diabetes Control
Novo hopes slimmed-down bet can still win in obesity
Novo Nordisk’s semaglutide is headed toward a Lilly showdown. Will Novo speed it up?
Novo’s next big diabetes bet heads to regulators
Lilly’s under-pressure Trulicity scores with first-of-its-kind cardio outcomes win
Novo Nordisk boosts its GLP-1 score with yet more evidence for crucial semaglutide pill
Got tech ideas for diabetes? Novo wants you for its crowdsourcing challenge
Lilly makes waves with next-generation diabetes drug, but GLP-1 rivals needn’t panic: analysts
As Diabetes Market Competition Heats up, Novo Nordisk to Cut 250 Jobs in U.S.
The approval case for Novo Nordisk’s oral GLP-1 diabetes candidate keeps on building, this time with new data in patients with kidney troubles. Monday, the Danish drugmaker said that in a phase … Continue Reading Novo data buttress its oral semaglutide case, this time in kidney-impaired patients